Denosumab Versus Zoledronic Acid for Patients With Beta-Thalassemia Major-Induced Osteoporosis

Trial Profile

Denosumab Versus Zoledronic Acid for Patients With Beta-Thalassemia Major-Induced Osteoporosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2018

At a glance

  • Drugs Denosumab (Primary) ; Zoledronic acid (Primary)
  • Indications Osteoporosis
  • Focus Therapeutic Use
  • Acronyms DOHA
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 May 2018 Planned number of patients changed from 20 to 40.
    • 29 May 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top